Cantor Fitzgerald Brokers Lift Earnings Estimates for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGLGet Rating) – Equities research analysts at Cantor Fitzgerald raised their FY2022 earnings per share (EPS) estimates for Rigel Pharmaceuticals in a report issued on Wednesday, August 3rd. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings per share of ($0.52) for the year, up from their previous forecast of ($0.53). Cantor Fitzgerald currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is ($0.52) per share. Cantor Fitzgerald also issued estimates for Rigel Pharmaceuticals’ FY2023 earnings at ($0.31) EPS.

Rigel Pharmaceuticals (NASDAQ:RIGLGet Rating) last issued its quarterly earnings results on Tuesday, May 3rd. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Rigel Pharmaceuticals had a negative net margin of 95.51% and a negative return on equity of 406.57%. The company had revenue of $16.74 million for the quarter, compared to the consensus estimate of $18.49 million. During the same quarter in the previous year, the business earned $0.22 earnings per share.

Several other research firms also recently commented on RIGL. B. Riley reduced their price objective on Rigel Pharmaceuticals from $4.00 to $1.25 and set a “neutral” rating for the company in a report on Thursday, June 9th. BMO Capital Markets cut their price target on Rigel Pharmaceuticals from $7.00 to $3.00 in a research note on Thursday, June 9th. Citigroup downgraded Rigel Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $7.00 to $0.80 in a research note on Thursday, June 9th. Piper Sandler downgraded Rigel Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price target for the company from $7.00 to $1.00 in a research note on Wednesday, June 8th. Finally, Jefferies Financial Group downgraded Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, June 8th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $2.34.

Rigel Pharmaceuticals Price Performance

NASDAQ RIGL opened at $1.52 on Friday. Rigel Pharmaceuticals has a one year low of $0.64 and a one year high of $4.24. The stock has a 50-day moving average of $1.24 and a 200 day moving average of $2.15. The company has a market capitalization of $261.52 million, a price-to-earnings ratio of -3.10 and a beta of 1.63. The company has a debt-to-equity ratio of 4.39, a quick ratio of 2.23 and a current ratio of 2.19.

Insider Buying and Selling

In other Rigel Pharmaceuticals news, CEO Raul R. Rodriguez purchased 1,000,000 shares of the stock in a transaction that occurred on Thursday, June 9th. The shares were bought at an average cost of $0.69 per share, with a total value of $690,000.00. Following the acquisition, the chief executive officer now owns 1,391,776 shares in the company, valued at $960,325.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.43% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in RIGL. SG Americas Securities LLC purchased a new stake in shares of Rigel Pharmaceuticals during the 2nd quarter worth approximately $224,000. Assenagon Asset Management S.A. increased its position in shares of Rigel Pharmaceuticals by 120.4% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,659,746 shares of the biotechnology company’s stock valued at $1,876,000 after purchasing an additional 906,636 shares during the last quarter. Strs Ohio increased its position in shares of Rigel Pharmaceuticals by 6.0% during the 2nd quarter. Strs Ohio now owns 163,200 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 9,200 shares during the last quarter. Bank of America Corp DE increased its position in shares of Rigel Pharmaceuticals by 10.1% during the 1st quarter. Bank of America Corp DE now owns 275,117 shares of the biotechnology company’s stock valued at $822,000 after purchasing an additional 25,128 shares during the last quarter. Finally, Walleye Capital LLC increased its position in shares of Rigel Pharmaceuticals by 43.8% during the 1st quarter. Walleye Capital LLC now owns 1,049,059 shares of the biotechnology company’s stock valued at $3,137,000 after purchasing an additional 319,762 shares during the last quarter. 80.33% of the stock is owned by hedge funds and other institutional investors.

Rigel Pharmaceuticals Company Profile

(Get Rating)

Rigel Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia.

Read More

Earnings History and Estimates for Rigel Pharmaceuticals (NASDAQ:RIGL)

Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.